{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Platelets+volume&page=2",
    "query": {
      "intervention": "Platelets volume",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Platelets+volume&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-14T05:03:35.826Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00367991",
      "title": "Effects of Recombinant Human Erythropoietin on Platelet Function in Patients With Acute Myocardial Infarction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myocardial Infarction"
      ],
      "interventions": [
        {
          "name": "Recombinant human erythropoietin alfa (drug)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "21 Years to 75 Years"
      },
      "enrollment_count": 44,
      "start_date": "2006-11",
      "completion_date": "2008-03",
      "has_results": true,
      "last_update_posted_date": "2018-01-12",
      "last_synced_at": "2026-09-14T05:03:35.826Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00367991"
    },
    {
      "nct_id": "NCT03232424",
      "title": "NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma, Adult"
      ],
      "interventions": [
        {
          "name": "NovoTTF-200A",
          "type": "DEVICE"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "3D conformal or intensity modulated radiation therapy (IMRT)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Hackensack Meridian Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2017-07-26",
      "completion_date": "2022-12-07",
      "has_results": false,
      "last_update_posted_date": "2024-11-18",
      "last_synced_at": "2026-09-14T05:03:35.826Z",
      "location_count": 1,
      "location_summary": "Hackensack, New Jersey",
      "locations": [
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03232424"
    },
    {
      "nct_id": "NCT04670965",
      "title": "Release Kinetics of rhBMP-2 Using E-PRF as an Autologous Carrier: An In Vitro Analysis",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Bone Loss"
      ],
      "interventions": [
        {
          "name": "E-PRF/rhBMP-2 (similar ratios)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "E-PRF/ACS/rhBMP-2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rhBMP-2/E-PRF",
          "type": "BIOLOGICAL"
        },
        {
          "name": "E-PRF only",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 20,
      "start_date": "2026-09",
      "completion_date": "2028-07",
      "has_results": false,
      "last_update_posted_date": "2026-04-20",
      "last_synced_at": "2026-09-14T05:03:35.826Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04670965"
    },
    {
      "nct_id": "NCT00283816",
      "title": "Impact of Metformin in Teens With Polycystic Ovary Syndrome (PCOS) on Oral Contraceptive Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Polycystic Ovary Syndrome"
      ],
      "interventions": [
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Oral Contraceptive Pill",
          "type": "DRUG"
        },
        {
          "name": "Lifestyle Management Program",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Quality of Life Questionnaire",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Oral Glucose Tolerance Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Blood work",
          "type": "PROCEDURE"
        },
        {
          "name": "Abdominal Ultra Sound",
          "type": "PROCEDURE"
        },
        {
          "name": "Dual-energy x-ray absorptiometry (DEXA scan)",
          "type": "PROCEDURE"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL",
        "PROCEDURE"
      ],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "18 Years",
        "sex": "FEMALE",
        "summary": "12 Years to 18 Years · Female only"
      },
      "enrollment_count": 36,
      "start_date": "2006-01",
      "completion_date": "2008-01",
      "has_results": true,
      "last_update_posted_date": "2015-05-15",
      "last_synced_at": "2026-09-14T05:03:35.826Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00283816"
    },
    {
      "nct_id": "NCT00003138",
      "title": "Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Anemia",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "Erythropoietin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Transfusion",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Eastern Cooperative Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 118,
      "start_date": "1998-03-04",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2023-06-29",
      "last_synced_at": "2026-09-14T05:03:35.826Z",
      "location_count": 28,
      "location_summary": "Denver, Colorado • Chicago, Illinois • Peoria, Illinois + 23 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Urbana",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003138"
    },
    {
      "nct_id": "NCT03222609",
      "title": "A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelofibrosis (MF)"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        },
        {
          "name": "Navitoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 191,
      "start_date": "2017-10-31",
      "completion_date": "2025-01-29",
      "has_results": true,
      "last_update_posted_date": "2026-01-20",
      "last_synced_at": "2026-09-14T05:03:35.826Z",
      "location_count": 33,
      "location_summary": "Birmingham, Alabama • Cerritos, California • Duarte, California + 27 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03222609"
    },
    {
      "nct_id": "NCT03165734",
      "title": "A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Myelofibrosis",
        "Post-polycythemia Vera Myelofibrosis",
        "Post-essential Thrombocythemia Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "Pacritinib",
          "type": "DRUG"
        },
        {
          "name": "Physician's Choice medications",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Swedish Orphan Biovitrum",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 407,
      "start_date": "2017-06-26",
      "completion_date": "2028-10-13",
      "has_results": false,
      "last_update_posted_date": "2026-04-30",
      "last_synced_at": "2026-09-14T05:03:35.826Z",
      "location_count": 42,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 29 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03165734"
    },
    {
      "nct_id": "NCT06158828",
      "title": "Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "AML, Childhood",
        "Aml",
        "Acute Myeloid Leukemia, Pediatric",
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Rabbit Anti thymocyte globulin",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "TCR alpha beta / CD19+ depleted haploidentical hematopoietic progenitor cell graft",
          "type": "BIOLOGICAL"
        },
        {
          "name": "memory-like natural killer cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IL-2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Plerixafor",
          "type": "DRUG"
        },
        {
          "name": "Granulocyte Colony-Stimulating Factor",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CliniMACS",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "DEVICE"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 68,
      "start_date": "2024-11-15",
      "completion_date": "2030-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-24",
      "last_synced_at": "2026-09-14T05:03:35.826Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06158828"
    },
    {
      "nct_id": "NCT07460440",
      "title": "SPARC - Screening for Lung Cancer With Platelets Via an AI-enabled RNA-based Classifier",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Lung Cancer",
        "Lung Nodule"
      ],
      "interventions": [
        {
          "name": "Platelet RNA-based assay",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 240,
      "start_date": "2026-09-01",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-09-14T05:03:35.826Z",
      "location_count": 2,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07460440"
    },
    {
      "nct_id": "NCT04201704",
      "title": "Effect of Giving Reduced Fluid in Children After Trauma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Critical Illness",
        "Pediatrics",
        "General Surgery",
        "Fluid Therapy",
        "Wounds and Injuries"
      ],
      "interventions": [
        {
          "name": "Balanced crystalloid solution volume administration",
          "type": "OTHER"
        },
        {
          "name": "Packed Erythrocytes Units, Blood Product Unit volume",
          "type": "OTHER"
        },
        {
          "name": "Plasma volume",
          "type": "OTHER"
        },
        {
          "name": "Platelets volume",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "15 Years",
        "sex": "ALL",
        "summary": "6 Months to 15 Years"
      },
      "enrollment_count": 250,
      "start_date": "2018-08-27",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2026-05-07",
      "last_synced_at": "2026-09-14T05:03:35.826Z",
      "location_count": 4,
      "location_summary": "Buffalo, New York • New York, New York • Rochester, New York + 1 more",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04201704"
    }
  ]
}